Update on Tutivia™ test adoption
Verici Dx PLC reported progress in Tutivia test adoption following their July equity fundraise. In Q3, the company saw a 19% increase in ordering clinicians and added nine new transplant centers, bringing the total to 30 onboarded centers. These centers represent 16% of annual transplants in the US. The company also expanded its commercial team with three new senior sales hires and will add a Director of Clinical Partnerships in mid-October. The number of orders in Q3 were consistent with the previous two quarters, and volume growth from recent progress is expected from Q4. The Board continues to target meeting market expectations for the full year.
Select text to share a quote on X · sign in to keep highlights & notes in your VRCI notes
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces positive progress in its plans to drive strong Tutivia™ sales growth following the equity fundraise completed in July.
Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters.
The Company has expanded its commercial team with three new senior sales hires. In addition, a Director of Clinical Partnerships will be joining the commercial team in mid-October.
The Board continues to target meeting market expectations for the full year.
Investor presentation
Sara Barrington, Chief Executive Officer, and David Anderson, Chief Financial Officer, will provide a live presentation via the Investor Meet Company platform on 7 October at 10.00 am BST. This presentation is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:
Investors who already follow Verici Dx on the Investor Meet Company platform will automatically be invited.
| Verici Dx plc | www.vericidx.com |
| Sara Barrington, CEO | Via Walbrook PR |
| Singer Capital Markets (Nominated adviser and Joint Broker) | Tel: +44 (0)20 7496 3000 |
| Phil Davies / Sam Butcher | |
| Oberon Capital (Joint Broker) | Tel: +44 (0)20 3179 0500 |
| Mike Seabrook / Adam Pollock | |
| Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com |
| Alice Woodings / Paul McManus | Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.